Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$35.00 USD
-2.22 (-5.96%)
Updated Aug 1, 2025 04:00 PM ET
Pre-Market: $29.61 -5.39 (-15.40%) 8:32 AM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Agios Pharmaceuticals, Inc. has a market cap of $2.03B, which represents its share price of $35.00 multiplied by its outstanding shares number of 58.10M. As a mid-cap company, AGIO's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AGIO 35.00 -2.22(-5.96%)
Will AGIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Other News for AGIO
12 Health Care Stocks Moving In Monday's Pre-Market Session
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Agios Pharmaceuticals (AGIO) Shares Cross Below 200 DMA
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight
Q2 2025 Agios Pharmaceuticals Inc Earnings Call Transcript